A

AbbVie

Global biopharmaceutical company developing medicines

Head Global Neuroimmunology Pipeline – Senior Scientific Director / Executive Medical Director - Medical Affairs

Full-TimeUpdated on 10/23/2026
$206.5k - $393k/yr+ Long-term incentive program
Senior, Expert
PharmD, PhD, MD, Doctor of Veterinary Medicine (DVM)
Florham Park, NJ, USA+1 moreMore locations: Mettawa, IL, USA
HybridHybrid schedule: 3 days/week onsite; based at Florham Park, NJ or Mettawa, IL.
Biology & Biotech

About the job

Requirements
  • An advanced degree (PhD, PharmD, or DVM) is required; post-doctoral or residency experience is preferred.
  • For the Senior Director title, an advanced degree and a minimum of 10 years of experience in clinical trials or medical affairs in the pharmaceutical industry or academia are required; typically, 15 years of overall experience.
  • For the Executive Medical Director title, an MD and a minimum of 5 years of clinical trial or medical affairs experience are required; 7 or more years of overall experience are preferred.
  • Strong leadership and cross-functional team management skills in a global environment are required.
  • Expertise in a Neuroimmunology therapeutic area and the ability to provide scientific strategy and support are required.
  • The ability to independently lead clinical studies or medical affairs teams is required.
  • Knowledge of clinical trial methodology, regulatory requirements, and protocol design is required.
  • Excellent oral and written communication skills in English are required.
  • People management experience is preferred.
Responsibilities
  • Lead, oversee, and support assigned indications and projects in collaboration with cross-functional teams across Medical, Clinical Development, Commercial, Market Access, and HEOR.
  • Initiate and manage medical affairs activities, data generation, and dissemination to advance scientific and business objectives.
  • Provide scientific and technical support for assets, deliver presentations, maintain relationships with key opinion leaders, and contribute to cross-functional teams.
  • Guide development of Target Product Profiles, contribute to Phase II–III trial design, and lead Phase 3b/4 strategies in alignment with the Target Product Profile.
  • Lead planning and execution of advisory boards and scientific and medical education programs for internal and external stakeholders.
  • Stay current on scientific advancements and literature; act as a resource for Psychiatry and other relevant therapeutic areas; and initiate and publish research projects.
  • Lead cross-functional teams on projects involving data analysis, expert engagement, publications, and collaborations.
  • Represent Medical Affairs in due diligence activities for asset acquisitions aligned with disease area strategy.
  • Ensure scientific initiatives meet budget, timeline, and compliance requirements.
  • Manage a team of high-performing colleagues.
Desired Qualifications
  • Post-doctoral or residency experience.
  • For the Executive Medical Director option, 7 or more years of overall experience.
  • People management experience.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Yahoo Finance
Oct 19th, 2026
Buffett warns of a "gambling mood" in markets; Vertex, Eli Lilly and AbbVie built to weather a drop

Warren Buffett, now Berkshire Hathaway's chairman emeritus, gave his bluntest warning yet at the May shareholder meeting. "We've never had people in a more gambling mood than now," he told CNBC, pointing to individuals rushing into short-term options and betting on markets. He said this behaviour is risky for those taking part and may threaten the market, possibly leading to a drop. The article suggests drugmakers as defensive picks, since patients need treatments in any economy. Vertex Pharmaceuticals leads in cystic fibrosis treatment. Eli Lilly's tirzepatide drugs, Mounjaro and Zepbound, earned more than $14 billion of its $23 billion quarterly revenue. AbbVie's Rinvoq and Skyrizi each grew 24%, and it has raised its dividend for more than 50 consecutive years.

Yahoo Finance
Oct 18th, 2026
Ken Griffin's Citadel boosts AbbVie stake 546% in Q2 as defensive dividend play

Citadel founder and chief executive officer Ken Griffin made healthcare his biggest bet in the second quarter. He bought 2.7 million AbbVie shares, a 546% increase from the previous quarter, and added 6.7 million shares of Abbott Laboratories, up 349%. He also raised his Eli Lilly stake by 291%, the third-biggest individual equity add. The moves suggest a defensive stance. Healthcare stocks tend to hold up in downturns, and both AbbVie and Abbott are Dividend Kings, having raised dividends for 54 straight years. AbbVie yields 2.65% and trades at 16 times forward earnings. In the second quarter, its adjusted earnings rose 23% and net revenue rose 10%. Some 75% of analysts covering the stock rate it a buy.